Lipoprotein(a) Measurement Frequency
Yes, Lp(a) needs to be measured only once in a lifetime for most adults, because it is genetically determined and remains stable throughout life. 1, 2
Core Recommendation
- Measure Lp(a) once in all adults as a universal screening recommendation, supported by both the European Society of Cardiology and National Lipid Association. 1
- No repeat testing is required unless the initial measurement was performed in childhood or early adulthood, in which case a single repeat measurement in adulthood is advised. 1
Why Only Once?
- Lp(a) levels are more than 90% genetically determined and do not change significantly over time in response to lifestyle, diet, or most medications. 3
- Biological stability has been confirmed in retrospective studies showing very low rates of false positives (0.3-0.6%) and false negatives (0.8-1%) when comparing repeated measurements, regardless of the threshold used (50,70,100, or 180 mg/dL). 4
- The 2025 ESC/EAS guidelines reinforce universal Lp(a) assessment at least once in adulthood to identify individuals at elevated cardiovascular risk. 5
Exceptions Requiring Measurement
If Lp(a) has never been measured, prioritize testing immediately in these high-risk populations:
- Premature ASCVD: Men <55 years or women <65 years with cardiovascular events not fully explained by traditional risk factors. 1
- Familial hypercholesterolemia: Elevated Lp(a) frequently coexists and compounds risk. 1, 2
- Recurrent or progressive ASCVD despite optimal lipid-lowering therapy. 1, 2
- Family history of premature ASCVD or known high Lp(a) in first-degree relatives. 1
- Intermediate 10-year ASCVD risk (7.5-19.9%) when considering statin initiation, as high Lp(a) reclassifies risk upward. 1, 2
Clinical Implications of a Single Measurement
- Lp(a) ≥50 mg/dL (≈125 nmol/L) is considered a risk-enhancing factor warranting intensified management of all modifiable cardiovascular risk factors. 1, 2
- Lp(a) ≥60 mg/dL (≈150 nmol/L) represents very high risk and may qualify select patients with familial hypercholesterolemia for lipoprotein apheresis if LDL-C remains ≥100 mg/dL despite maximal therapy. 1
- Once identified, management focuses on aggressive LDL-C lowering (high-intensity statin ± ezetimibe or PCSK9 inhibitor) and control of hypertension, smoking, diabetes, and obesity—not on repeat Lp(a) testing. 1, 2
Common Pitfalls
- Do not recheck Lp(a) to monitor therapy, as current lipid-lowering drugs do not reliably lower Lp(a), and statins or ezetimibe may even raise it slightly. 1
- Assay standardization remains incomplete, so verify the laboratory method and reference range; conversion between mg/dL and nmol/L uses an approximate factor of 3.17. 1, 2
- Avoid using niacin solely to lower Lp(a), as clinical trials have not demonstrated cardiovascular benefit despite 20-30% reductions in Lp(a). 2